Edwards Lifesciences: With A Heart Beating Strong And Steady
Edwards Lifesciences is a high-quality, dominant player in structural heart medical devices, with a solid growth history and strong cash generation. The TMTT segment is now the main growth engine, showing rapid expansion, while TAVR growth has plateaued but remains stable. Strategic acquisitions and robust R&D investment position EW for continued innovation and long-term revenue growth above S&P 500 averages.
Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock
EW's new late-breaking clinical data shows early intervention in AS may slash significant costs and improve patient outcomes.
Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes
PARIS--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing to the extensive body of research on this disease. The results of a new real-world study of more than 24,000 patients demonstrated that intervening on the disease before symptoms develop reduces the economic and resource burden on the healthcare system and improves patient outco.
Trade Tracker: Bill Baruch buys Edwards Lifesciences
Bill Baruch, founder & president at Blue Line Capital, joins CNBC's 'Halftime Report' to detail his latest buy.
Should Edwards Lifesciences Stock Remain in Your Portfolio Now?
EW stock is on investors' radars due to the promising structural heart opportunities and impressive TMTT portfolio.
EW Q1 Earnings & Revenues Beat, Stock Climbs, '25 Sales View Raised
Edwards Lifesciences' first-quarter 2025 performance benefits from its differentiated portfolio of therapies to treat patients with structural heart disease.
Edwards Lifesciences Corporation (EW) Q1 2025 Earnings Call Transcript
Edwards Lifesciences Corporation (NYSE:EW ) Q1 2025 Earnings Conference Call April 23, 2025 5:00 PM ET Company Participants Mark Wilterding - SVP, Global Finance Bernard Zovighian - CEO Scott Ullem - CFO Daveen Chopra - Global Leader, TMTT Larry Wood - Global Group President, TAVR and Surgical Conference Call Participants Larry Biegelsen - Wells Fargo David Roman - Goldman Sachs Travis Steed - Bank of America Robbie Marcus - JPMorgan Vijay Kumar - Evercore ISI Matt Taylor - Jefferies Joanne Wuensch - Citibank Pito Chickering - Deutsche Bank Chris Pasquale - Nephron Patrick Wood - Morgan Stanley Operator Greetings, and welcome to the Edwards Lifesciences First Quarter 2025 Results. [Operator Instructions] As a reminder, this conference is being recorded.
Edwards Lifesciences (EW) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Edwards Lifesciences (EW) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Unlocking Q1 Potential of Edwards Lifesciences (EW): Exploring Wall Street Estimates for Key Metrics
Evaluate the expected performance of Edwards Lifesciences (EW) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Solid TMTT Growth to Drive Edwards Lifesciences' Q1 Earnings
EW's first-quarter 2025 performance is likely to have gained from growth drivers across its businesses amid macroeconomic headwinds.
Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwards L.
New Data Confirm Rapid, Unpredictable Progression of Severe Aortic Stenosis and Need for Urgent Referral and Evaluation of Patients
CHICAGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new scientific evidence presented and published during the American College of Cardiology's (ACC) Annual Scientific Session & Expo, addressing the critical needs of patients with structural heart disease. Without treatment, 1 in 10 patients experiencing symptoms of severe aortic stenosis (AS) may die within five weeks. However, the symptoms of severe AS can be difficult to detect and may progress rapidly and unpredict.
